SBC Medical Group Holdings Inc
NASDAQ:SBC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
SBC Medical Group Holdings Inc
NASDAQ:SBC
|
US |
|
Itaconix PLC
LSE:ITX
|
UK |
|
Chongqing Baiya Sanitory Products Co Ltd
SZSE:003006
|
CN |
|
H
|
Huhtamaki Oyj
F:HUKI
|
FI |
|
T
|
Thye Ming Industrial Co Ltd
TWSE:9927
|
TW |
|
HF Sinclair Corp
NYSE:DINO
|
US |
|
L&T Finance Ltd
NSE:LTF
|
IN |
|
Schindler Holding AG
OTC:SHLRF
|
CH |
|
OSB Group PLC
OTC:OSBGF
|
UK |
|
Powszechny Zaklad Ubezpieczen SA
F:7PZ0
|
PL |
|
Westaim Corp
XTSX:WED
|
CA |
|
F
|
Foraco International SA
OTC:FRACF
|
FR |
|
Summerset Group Holdings Ltd
NZX:SUM
|
NZ |
|
S
|
SIG PLC
SWB:QIG
|
UK |
|
D
|
Derwent London PLC
SWB:DVK
|
UK |
|
Kunlun Tech Co Ltd
SZSE:300418
|
CN |
|
S
|
Sunway Real Estate Investment Trust
KLSE:SUNWAY
|
MY |
|
C
|
Cochlear Ltd
XMUN:OC5
|
AU |
|
Signet Jewelers Ltd
NYSE:SIG
|
BM |
|
U
|
Unite Group PLC
OTC:UTGPF
|
UK |
|
Hankyu Hanshin Holdings Inc
OTC:HYUHF
|
JP |
SBC Medical Group Holdings Inc
SBC Medical Group Holdings Inc. is a medical aesthetics company tied to cosmetic and skin-care clinics, especially in Japan. It helps run and expand clinics that offer treatments such as cosmetic surgery, dermatology, and beauty procedures. The company sits behind the clinic network by handling the business side of the operation rather than just seeing patients itself. It makes money mainly by supporting clinics with management services, branding, marketing, training, procurement, and other back-office work. It may also earn fees from franchise-style arrangements and from selling products used in or around clinic operations. Its main customers are clinic operators and, indirectly, the patients who use those clinics for cosmetic treatments. What makes its business model different is that it is not a standard hospital or drugmaker. It acts more like a specialized service partner for aesthetic clinics, helping them open, grow, and run more consistently under a shared system. That gives it a role in the value chain between the medical providers and the consumer-facing clinics.
SBC Medical Group Holdings Inc. is a medical aesthetics company tied to cosmetic and skin-care clinics, especially in Japan. It helps run and expand clinics that offer treatments such as cosmetic surgery, dermatology, and beauty procedures. The company sits behind the clinic network by handling the business side of the operation rather than just seeing patients itself.
It makes money mainly by supporting clinics with management services, branding, marketing, training, procurement, and other back-office work. It may also earn fees from franchise-style arrangements and from selling products used in or around clinic operations. Its main customers are clinic operators and, indirectly, the patients who use those clinics for cosmetic treatments.
What makes its business model different is that it is not a standard hospital or drugmaker. It acts more like a specialized service partner for aesthetic clinics, helping them open, grow, and run more consistently under a shared system. That gives it a role in the value chain between the medical providers and the consumer-facing clinics.
Strong quarter: SBC said Q2 2026 revenue was $49 million, up 13% year-on-year, while adjusted EBITDA rose 32% to $20 million and margin improved to 41%.
Reacceleration: Management said 2025 restructuring is complete and growth has reaccelerated, helped by higher customer volume, higher spend per visit, and stronger management services revenue.
Fee upside: The company highlighted about $15 million of annual fee upside from service revisions, with part of that starting to flow through in late 2026 and fuller impact expected next fiscal year.
AI push: SBC is using AI to improve clinic operations, customer service, site selection, and staff training, and says AI should help both efficiency and sales without materially raising fixed costs.
Expansion plan: The company is pushing multi-brand aesthetics, non-aesthetic health care, U.S. expansion through OrangeTwist, and asset-light Southeast Asia growth, while keeping a 2035 target of 1,000 clinics.
Capital focus: Management said cash is ample and the goal is to grow EPS and normalize valuation through organic growth, disciplined M&A, and broader investor outreach.